First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology

(2012) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1  in Advanced Solid Tumors

(2011) S. Kummar et al.   CLINICAL CANCER RESEARCH

Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101

(2011) Sonke Svenson et al.   JOURNAL OF CONTROLLED RELEASE

Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer

(2011) Shikha Gaur et al.   Nanomedicine-Nanotechnology Biology and Medicine

Inhibition of Hypoxia-Inducible Factor-1α (HIF-1α) Protein Synthesis by DNA Damage Inducing Agents

(2010) Jessica Jie Wei Lou et al.   PLoS One

Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin

(2009) Mark E. Davis   ADVANCED DRUG DELIVERY REVIEWS

Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models

(2009) T. Numbenjapon et al.   CLINICAL CANCER RESEARCH

HIF-1α modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines

(2009) Yun Jung Choi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements

(2009) T. Schluep et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA